Ivo Díaz Ludovico

Ivo Díaz Ludovico

Auto-generated profile, based on publicly available information

Ivo Díaz Ludovico

Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2023 in Science Advances
Verified
Journal Article
Open access
NMNathaniel J. Merrill
Nathaniel J. Merrill
WDW. Sean Davidson
W. Sean Davidson
YHYi He
Yi He
ILIvo Díaz Ludovico
Ivo Díaz Ludovico
SSSnigdha Sarkar
Snigdha Sarkar
JMJohn Melchior
John Melchior
Lipoproteins in cerebrospinal fluid (CSF) of the central nervous system (CNS) resemble plasma high-density lipoproteins (HDLs), which are a compositionally and structurally diverse spectrum of nanoparticles with pleiotropic functionality. Whether CSF lipoproteins (CSF-Lps) exhibit similar heterogeneity is poorly understood because they are present at 100-fold lower concentrations than plasma HDL. To investigate the diversity of CSF-Lps, we developed a sensitive fluorescent technology to characterize lipoprotein subspecies in small volumes of human CSF. We identified 10 distinctly sized populations of CSF-Lps, most of which were larger than plasma HDL. Mass spectrometric analysis identified 303 proteins across the populations, over half of which have not been reported in plasma HDL. Computational analysis revealed that CSF-Lps are enriched in proteins important for wound healing, inflammation, immune response, and both neuron generation and development. Network analysis indicated that different subpopulations of CSF-Lps contain unique combinations of these proteins. Our study demonstrates that CSF-Lp subspecies likely exist that contain compositional signatures related to CNS health.

28 April 2016 in Atherosclerosis
Verified
Journal Article
Closed access
PDF file
ALAngelo Ledda
Angelo Ledda
MGMarina González
Marina González
JGJosé Gulfo
José Gulfo
ILIvo Díaz Ludovico
Ivo Díaz Ludovico
NRNahuel Ramella
Nahuel Ramella
Montserrat EsteveMontserrat Esteve
Montserrat Esteve

16 September 2025 in Proteomics
Verified
Journal Article
Open access
PDPanshak Dakup
Panshak Dakup
ILIvo Diaz Ludovico
Ivo Diaz Ludovico
YYYoungki You
Youngki You
Chaitra RaoChaitra Rao
Chaitra Rao
JFJavier E Flores
Javier E Flores
ENErnesto Nakayasu
Ernesto Nakayasu
Extracellular vesicles (EVs) are membrane‐bound particles secreted by cells, playing crucial roles in intercellular communication. The composition of EVs can undergo changes in response to stress and disease conditions, making them excellent biomarker candidates. However, extracting protein information from EVs can be challenging due to their low abundance in complex biofluids and copurification with contaminant proteins and particles. Techniques to enrich EVs have their strengths and limitations, without one being able to purify EVs to complete homogeneity. This can lead to compromised recovery rates and increased complexity, making data interpretation difficult. In this viewpoint article, we explore the concept that better characterization of EV composition, followed by quantification of EV proteins in complex samples, might be a more viable route for biomarker development. Mass spectrometers can provide reproducible deep coverage of the EV proteome, despite sample impurities. This paradigm shift presents opportunities to integrate advanced bioinformatics tools to refine the EV proteome landscape, identify novel biomarkers, and streamline validation processes in biomarker development. By focusing on leveraging technology rather than achieving absolute purity, this approach can transform current practices and open opportunities for robust biomarker discovery. Herein, we highlight not only such opportunities but also challenges to implement this concept. Summary: Extracellular vesicles (EVs) have enormous potential as biomarkers of diseases, as they can carry signatures of the cells they are derived from and the pathogenesis process. Biofluids, such as blood plasma, are highly complex and contain many components with physicochemical properties similar to those of EVs, making it challenging to obtain pure EV fractions. Challenges in obtaining pure preparations represent a main hurdle for studying EVs, and their components are potential biomarkers. This article explores the concept of studying EV proteins within complex samples, discussing opportunities and needs to move this field forward.

1 January 2021 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
ILIvo Díaz Ludovico
Ivo Díaz Ludovico
RGRomina A. Gisonno
Romina A. Gisonno
MGMarina C. Gonzalez
Marina C. Gonzalez
HGHoracio A. Garda
Horacio A. Garda
NRNahuel A. Ramella
Nahuel A. Ramella
MTM. Alejandra Tricerri
M. Alejandra Tricerri

2 September 2023 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Open access
ILIvo Díaz Ludovico
Ivo Díaz Ludovico
SSSoumyadeep Sarkar
Soumyadeep Sarkar
EEEmily Elliott
Emily Elliott
SVSuvi M. Virtanen
Suvi M. Virtanen
IEIris Erlund
Iris Erlund
ENErnesto Nakayasu
Ernesto Nakayasu
Type 1 diabetes (T1D) is an autoimmune disease in which pro-inflammatory and cytotoxic signaling drive the death of the insulin-producing β cells. This complex signaling is regulated in part by fatty acids and their bioproducts, making them excellent therapeutic targets. We provide an overview of the fatty acid actions on β cells by discussing how they can cause lipotoxicity or regulate inflammatory response during insulitis. We also discuss how diet can affect the availability of fatty acids and disease development. Finally, we discuss development avenues that need further exploration. Fatty acids, such as hydroxyl fatty acids, ω-3 fatty acids and their downstream products, are druggable candidates that promote protective signaling. Inhibitors and antagonists of enzymes and receptors of arachidonic acid and free fatty acids, along with their derived metabolites, which cause pro-inflammatory and cytotoxic responses, have the potential to be developed as therapeutic targets also. Further, because diet is the main source of fatty acid intake in humans, balancing protective and pro-inflammatory/cytotoxic fatty acid levels through dietary therapy may have beneficial effects, delaying T1D progression. Therefore, therapeutic interventions targeting fatty acid signaling hold potential as avenues to treat T1D.

19 June 2024 in Proteomics
Verified
Journal Article
Open access
ILIvo Díaz Ludovico
Ivo Díaz Ludovico
SPSamantha M. Powell
Samantha M. Powell
GMGina Many
Gina Many
LBLisa Bramer
Lisa Bramer
SSSoumyadeep Sarkar
Soumyadeep Sarkar
ENErnesto Nakayasu
Ernesto Nakayasu
Extracellular vesicles (EVs) carry diverse biomolecules derived from their parental cells, making their components excellent biomarker candidates. However, purifying EVs is a major hurdle in biomarker discovery since current methods require large amounts of samples, are time‐consuming and typically have poor reproducibility. Here we describe a simple, fast, and sensitive EV fractionation method using size exclusion chromatography (SEC) on a fast protein liquid chromatography (FPLC) system. Our method uses a Superose 6 Increase 5/150, which has a bed volume of 2.9 mL. The FPLC system and small column size enable reproducible separation of only 50 µL of human plasma in 15 min. To demonstrate the utility of our method, we used longitudinal samples from a group of individuals who underwent intense exercise. A total of 838 proteins were identified, of which, 261 were previously characterized as EV proteins, including classical markers, such as cluster of differentiation (CD)9 and CD81. Quantitative analysis showed low technical variability with correlation coefficients greater than 0.9 between replicates. The analysis captured differences in relevant EV proteins involved in response to physical activity. Our method enables fast and sensitive fractionation of plasma EVs with low variability, which will facilitate biomarker studies in large clinical cohorts.